Amyloid beta, 1-42, HFIP-treated Purified Peptide

Only %1 left
Catalog Number
PE-1749
Discontinued

    Product Info

  • Product Name Amyloid beta, 1-42, HFIP-treated Purified Peptide
  • Product Description google Synthetic beta-amyloid Aβ1-42 was monomerized by HFIP (hexafluoro-2-propanol) treatment and dried. One vial contains 50 μg monomeric Aβ peptide that can be used to form solutions of unaggregated Aβ monomers, aggregated Aβ oligomers, Aβ fibrils and Aβ protein complexes according to published protocols, and used in a variety of research applications.
  • Alternative Names Beta-APP42; Beta-amyloid protein 42; ABPP; APPI; Amyloid beta A4 protein; AB42; abeta
  • Application(s) ELISA
  • Purity Description Purified
  • Regulatory Status For research use only.

    Specifications

  • Product Description Synthetic beta-amyloid Aβ1-42 was monomerized by HFIP (hexafluoro-2-propanol) treatment and dried. One vial contains 50 μg monomeric Aβ peptide that can be used to form solutions of unaggregated Aβ monomers, aggregated Aβ oligomers, Aβ fibrils and Aβ protein complexes according to published protocols, and used in a variety of research applications.
  • Related Products Oligomeric Amyloid-beta, Human, Rat, ELISA assay
    Apolipoprotein E/beta-Amyloid Complex (ApoE/A beta), Human, ELISA assay
    Amyloid beta peptide (A-beta 40/42), Mouse Monoclonal Antibody
    Amyloid beta peptide (A-beta 40/42), Mouse Monoclonal Antibody (Biotin)
    Amyloid beta, 1-42, oligomeric, Stabilized Peptide
  • Application(s) ELISA
  • Application Details Preparation of unaggregated A-beta1-42:

    Important: unaggregated A-beta has to be prepared just prior to use!

    1. Add 5 µL of reconstituting buffer to one vial of 50 µg of HFIP-treated A-beta peptide; spin down the liquid briefly
    2. Vortex the vial for 5 seconds at highest speed while rotating the vial with your hands; spin down the liquid (bench-top microcentrifuge) and repeat the vortex-spin procedure for a minimum of 3 times; continue the vortex-spin procedure until all lyophilized peptide is dissolved and collected at the bottom of the tube. Important: refer to the attached instructions for a detailed procedure to ensure that all peptide is fully reconstituted!
    3. Add 106 µL of cold Dilution Buffer to make up to 111 µL total volume and a peptide concentration of 100 µM. Vortex-spin for 3 more times
    4. Final concentration of A-beta is 450 µg/mL
    5. Use reconstituted peptide immediately to avoid oligomer formation

    Preparation of oligomeric A-beta1-42:

    1. Add 5 µL of reconstituting buffer to one vial of 50 µg of HFIP-treated A-beta peptide; spin down the liquid briefly
    2. Vortex the vial for 5 seconds at highest speed while rotating the vial with your hands; spin down the liquid (bench-top microcentrifuge) and repeat the vortex-spin procedure for a minimum of 3 times; continue the vortex-spin procedure until all lyophilized peptide is dissolved and collected at the bottom of the tube. Important: refer to the attached instructions for a detailed procedure to ensure that all peptide is fully reconstituted!
    3. Add 106 µL of cold Dilution Buffer to make up to 111 µL total volume and a peptide concentration of 100 µM
    4. Vortex-spin for 3 more times
    5. Incubate the solution at 2-8ºC for 24 hours (protected from light)
    6. Final concentration of A-beta is 450 µg/mL
    7. Once reconstituted and oligomerized, o-A-beta should be used as soon as possible and within 7 days to ensure the stability of the oligomers

    Note: while the concentration of monomeric A-beta peptide used to form the oligomeric complexes is accurately determined, the precise formation, size and number of oligomers cannot be quantified by any known method.

    Preparation of fibrillar A-beta1-42:

    1. Add 5 µL of reconstituting buffer to one vial of 50 µg of HFIP-treated A-beta peptide; spin down the liquid briefly
    2. Vortex the vial for 5 seconds at highest speed while rotating the vial with your hands; spin down the liquid (bench-top microcentrifuge) and repeat the vortex-spin procedure for a minimum of 3 times; continue the vortex-spin procedure until all lyophilized peptide is dissolved and collected at the bottom of the tube. Important: refer to the attached instructions for a detailed procedure to ensure that all peptide is fully reconstituted!
    3. Add 106 µL of 10 mM HCl to make up to 111 µL total volume and a peptide concentration of 100 µM
    4. Vortex-spin for 3 more times
    5. Incubate the solution at 37ºC for 24 hours (protected from light)
    6. Final concentration of A-beta is 450 µg/mL

    Preparation of A-beta1-42 Complexes:

    Important: only unagreggated A-beta will form complexes. Use A-beta peptide immediately after reconstitution to form complexes.

    1. Add 5 µL of reconstituting buffer to one vial of 50 µg of HFIP-treated A-beta peptide; spin down the liquid briefly
    2. Vortex the vial for 5 seconds at highest speed while rotating the vial with your hands; spin down the liquid (bench-top microcentrifuge) and repeat the vortex-spin procedure for a minimum of 3 times; continue the vortex-spin procedure until all lyophilized peptide is dissolved and collected at the bottom of the tube. Important: refer to the attached instructions for a detailed procedure to ensure that all peptide is fully reconstituted!
    3. Add 106 µL of cold Dilution Buffer to make up to 111 µL total volume and a peptide concentration of 100 µM
    4. Vortex-spin for 3 more times
    5. Use reconstituted peptide immediately to avoid oligomer formation
    6. Mix the A-beta monomer with its complex partner (eg., lipoprotein) at desired concentrations in PBS, pH 7.4, or other suitable buffers compatible with its intended application
    7. Incubate at room temperature for 2 hours without shaking
    8. Use complexes immediately after incubation

    These protocols are based on procedures published by Youmans KL et al., 2012 and Tai LM et al., 2013, and we refer to these publications and other relevant literature for further details.

    Provided working concentrations are only meant to guide the user. Optimal concentrations depend on the experimental design and need to be determined empirically.
  • Target Amyloid beta, 1-42
  • Target Host Species Human
  • Antigen Produced In Synthetic
  • Sequence DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
  • Kit Components 3 vials. 1 x 50 μg Abeta1-42 peptide; 1 x 100 μL Reconstituting Buffer, 1 x 1 mL Dilution Buffer
  • Purity Description Purified
  • Appearance Translucent film or droplets, dry, without preservatives.
  • Format Lyophilized.
  • Reconstitution Instructions Varies, dependent on intended use. Refer to Applications.
  • Storage Instructions Store unopened, dry Aβ peptide vial with desiccant, insulated, at -20°C short term, -80°C long term. Store the buffers at 2-8°C, do not freeze.
  • Batch Number Please see item label.
  • Expiration Date 12 months after date of receipt (unopened vial).
  • Alternative Names Beta-APP42; Beta-amyloid protein 42; ABPP; APPI; Amyloid beta A4 protein; AB42; abeta
  • Uniprot Number P05067
  • Uniprot Number/Name P05067 (A4_HUMAN)
  • Shipping Temperature 25°C (ambient)
  • UNSPSC CODE 41105330
  • Regulatory Status For research use only.

    Images, Protocols & SDS

  • Oligomeric A-beta standard curves generated with BEK-2215 (Oligomeric A beta ELISA kit). Pre-formed oligomers (PE-1750-1000) were reconstituted in assay buffer and compared to oligomers freshly prepared from HFIP-treated A-beta peptide (PE-1749-50). This data demonstrates the usefulness of PE-1749-50 as oligomeric A-beta protein standard.

    Citations & References

  • General References Youmans KL. et al. (2012) Intraneuronal Abeta detection in 5xFAD mice by a new Abeta-specific antibody. Mol Neurodegener. 2012 Mar 16;7(1):8.

    Tai LM. et al. (2013) Levels of Soluble Apolipoprotein E/Amyloid-beta (Aβ) Complex Are Reduced and Oligomeric Abeta Increased with APOE4 and Alzheimer Disease in a Transgenic Mouse Model and Human Samples. J Biol Chem. 2013 Feb 22;288(8):5914-26.